Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L. Mayer, Amylou C. Dueck, Miguel Martín, Gábor Rubovszky, Harold J. Burstein, M. Bellet-Ezquerra, Kathy D. Miller, Nicholas Zdenkowski, Eric P. Winer, Georg Pfeiler, Matthew P. Goetz, Manuel Ruíz‐Borrego, D. Mark Anderson, Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany A. Traina, Arlene Chan, Hope S. Rugo, Julie Lemieux, Fernando Henao, Alan P. Lyss, Silvia Antolín, Antonio C. Wolff, Marcus Vetter, Daniel Egle, Patrick G. Morris, Eleftherios P. Mamounas, Miguel Gil‐Gil, Aleix Prat, Hannes Fohler, Otto Metzger, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui R. Lu, Cynthia Huang Bartlett, María Koehler, Christian Fesl, Angela DeMichele, Michael Gnant
Topics & Concepts
PalbociclibInterim analysisMedicineInterimAdjuvantOncologyBreast cancerInternal medicineCancerEndocrine systemAdjuvant therapyGynecologyClinical trialMetastatic breast cancerHistoryHormoneArchaeologyAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research